摘要
目的 :观察雷公藤多甙治疗原发性系膜增殖性肾炎的疗效。方法 :86例经肾活检确诊为系膜增殖性肾炎患者MsPGN 49例、IgAN 30例、IgMN 7例 ,服用雷公藤多甙 2 0～ 40mg ,3·d-1,4～ 8周。结果 :治疗 4周内 45例 (5 2 .33% )病人获完全缓解 ,15例 (17.44 % )改善 ,治疗 8周内总有效率 87.2 1%。双倍剂量雷公藤多甙治疗组与常规剂量组 4周总有效率相比较 ,有极显著性差异 (P <0 .0 1)。结论 :雷公藤多甙对临床表现为肾病综合征、肾炎综合征 ,组织学病变为轻～中度系膜增殖的MsPGN、IgAN具有良好的疗效。
Objective:To evaluate the clinical effect of tripterygium wilfordii(TW) on primary mesagial proliferative glomerulonephritis.Methods:20～40 mg TW was given to 86 nephritis patients 3 times a day for 4-8 weeks,of whom included 49 mesagial proliferative glomerulonephritis (MsPGN),30 IgA nephropathy(IgAN) and 7 IgM nephropathy(IgMN).Results:Complete remission was observed in 45 patients(52.33%) within 4 weeks and 50 patients within 8 weeks.Higher remission rate was observed in those patients treated with double dosage of TW(40 mg×3·d -1 ).Conclusion:TW shows as an effective clinical treatment on MsPGN and IgAN.
出处
《西北国防医学杂志》
CAS
2001年第1期37-39,共3页
Medical Journal of National Defending Forces in Northwest China
关键词
原发性系膜增殖肾炎性
雷公藤多甙
药物治疗
Nephritis
Mesagial proliferative glomerulonephritis
Tripterygium wilfordii
